Codexis Collaborates With Leading Biopharmaceutical Company to Apply CodeEvolver Protein Engineering in Therapeutics Development Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Codexis (CDXS) Tops Q2 EPS by 7c
August 11, 2015 4:07 PM EDTCodexis (NASDAQ: CDXS) reported Q2 EPS of ($0.07), $0.07 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $6 million versus the consensus estimate of $7.34 million.
"Solid year-to-date progress executing our plans encourages us to raise both of our annual financial guidance measures at this stage. Total revenues and gross margin in the second quarter reflected notable strength in... More
Codexis (CDXS) Enters R&D Agreement with Leading Biopharma
August 11, 2015 7:29 AM EDTCodexis (NASDAQ: CDXS) announced that it has entered into a collaborative research and development agreement with a leading global biopharmaceutical company. This is the first significant agreement in which Codexis will apply its proprietary CodeEvolver® protein engineering platform technology with a company in the biopharmaceutical industry.
Under the terms of the agreement, Codexis will employ CodeEvolver to... More
